Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-553 in CLL/SLL and Aggressive Lymphoma
NCT03492125Phase 2Terminated
- Sponsor
- MingSight Pharmaceuticals
- Start
- May 2018
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MS-553 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), aggressive lymphoma, sponsored by MingSight Pharmaceuticals. Started May 2018; status: terminated.
02
Drugs
MS-553
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)aggressive lymphoma
Beyond the preview
Go deeper on NCT03492125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492125.